In the article are described literary given about the frequency, the mechanisms, the factors of the risk of hemotherapy-induced liver injury with conducting of antitumorigenic medicinal therapy for patients with different oncologic diseases. Is represented the substantiation and the clinical experience, which makes it possible to make a conclusion about the high efficiency of the use of ademethionin (Heptral) for overcoming this complication of polychemotherapy. Are represented the results of their own three-stage study, which make it possible to make a conclusion about the high frequency of hemotherapy-induced liver injury with conducting of polychemotherapy, the analysis of the significance of the number of the factors of the risk is carried out. It is proven that the accompanying therapy by ademethionin (Heptral) in the patients with the metastatic forms of cancer with the factors of risk of hemotherapy-induced liver injury contributes to the retention of the level of the syndromes of cholestasis and cytolysis at the levels, which make it possible in the majority of patients to continue the conducted treatment regimen of polychemotherapy.

Aim of this study was to analyze the karyological indicators in exfoliated cells in patients with cancer of the gastrointestinal tract. There was revealed statistically significant (p < 0.01) increase of all parameters in buccal and nasal epithelium in such kind of patients compared to healthy persons. These changes were systemic in nature and reflected the general state of the organism.

Представлены данные клинического обследования 48 человек (42 мужчины, 6 женщин) трудоспособного возраста (40-75 лет), больных местно-распространенным раком орофарингеальной области. Применен современный подход к лечению этих больных - таргетная терапия в неоадъювантном режиме с учетом биологического профиля опухоли. Применение гефитиниба приводило к выраженному противоопухолевому эффекту у 90.5% больных, против 56.5% без использования этого препарата.

Administration of an immunomodulator, galavit, for stage II-III non-small lung cancer along with standard therapy was followed by immunological vigor improvement by the end of the course. CD3, CD4, IgA, IgM and IgG indices were normal in more than 80% of the study group by day 51 after surgery; CD8, CD20 and HLA-DR--in more than 50%; CD16--in 45.2%. In control, by day 51, normal IgG and HLA-DR levels were reported in 60%. The remaining indices were normal in less than 50%. Our results point to immunological vigor improvement due to use of galavit. The drug is well tolerated, has neither side effects nor toxicity.

The article presents the results of a clinicoimmunological examination of 61 patients with stage II-III non-small cell cancer of the lung. It has been shown that in the presence of immunomodulating therapy all links of the immunity are being recovered.

A procedure for obtaining microcirculation coefficient is described. It is based on the phenomenon of formation of a focus of radionuclide hyperfixation on scintigrams of tumor area due to embolization of its arterioles and precapillaries with radionuclide. The method was used in 26 breast cancer patients before neoadjuvant chemotherapy. A direct correlation between the microcirculation coefficient and degree of tumor-induced pathomorphosis of tumor cells was established. The coefficient values proved more or less predictive of tumor response to chemotherapy.